See Bull Run's current company pages for Sun Pharmaceutical Industries and Lupin. Investors can also compare Sun's manufacturing-heavy peer in Bull Run's Sun Pharma vs Divi's Laboratories analysis.

Sun generated approximately 1.85 times Lupin's quarterly sales.

But the earnings gap was smaller. Sun's EBITDA was about 1.7 times Lupin's, and Sun's reported PAT was only about twice Lupin's. Lupin is therefore generating substantially more profit per rupee of revenue than it did during its weaker years.

Q1 FY27 financial scorecard

The biggest Q1 difference was the United States

Sun still generated greater absolute US pharmaceutical revenue.

But the growth trajectories moved in opposite directions.

Lupin is benefiting from several years of investment in differentiated products, complex generics and launches.

Sun's Innovative Medicines business continued growing, but weakness in legacy US generics offset part of that strength.

Why Lupin's US business is improving

Lupin's US strategy has increasingly shifted away from simple oral-solid generics toward products with higher scientific or regulatory barriers.

Its portfolio now includes:

• complex injectables;
• respiratory products;
• long-acting injectables;
• biosimilars;
• specialty respiratory medicines;
• complex oral products;
• 505(b)(2) opportunities.

The company says complex generics now represent roughly 40% of its US portfolio.

This matters because high-barrier products typically attract fewer competitors than commodity tablets.

Differentiated launches have changed Lupin's US economics

Products such as Mirabegron, Tolvaptan and Risperidone long-acting injectable have improved Lupin's product mix.

Tolvaptan benefited from first-to-file exclusivity during the prior growth cycle.

Lupin also launched the first product developed through its proprietary Nanomi long-acting injectable platform.

Respiratory products such as Tiotropium further demonstrate the company's ability to manufacture dosage forms that are difficult to replicate.

US scale is now strategically important for Lupin

Lupin remains the third-largest pharmaceutical company in the US generic market by prescriptions according to company-cited IQVIA data.

At the end of Q1 FY27 it marketed 149 generic products in the US.

It received six ANDA approvals and launched three products during the quarter.

Lupin was the market leader in 56 marketed generics and ranked among the top three in 112 products.

This creates manufacturing and commercial scale that smaller Indian peers cannot easily reproduce.

Sun is solving a different US problem

Sun is deliberately reducing its economic dependence on commoditised US generics.

Instead, it is building an Innovative Medicines platform.

Important products include:

• Ilumya in dermatology and immunology;
• Cequa in ophthalmology;
• Odomzo in oncology;
• Unloxcyt in oncology;
• a wider pipeline across dermatology, oncology and metabolic disease.

This is a fundamentally different economic strategy from launching complex generics.

Specialty medicine versus complex generic: what is the difference?

A complex generic attempts to replicate an existing approved therapy but can require difficult formulation, device, manufacturing or regulatory expertise.

An innovative or specialty medicine may involve proprietary clinical development, brand building and new intellectual property.

Complex generics generally carry lower clinical-development risk.

Innovative medicines can offer much higher long-term commercial value if they succeed.

They can also fail in clinical trials after substantial investment.

Sun therefore owns the larger innovation upside

Sun's Innovative Medicines pipeline includes programmes across:

• psoriasis;
• psoriatic arthritis;
• cutaneous cancers;
• melanoma;
• soft-tissue sarcoma;
• glioblastoma;
• diabetes;
• obesity.

This gives Sun opportunities that can eventually create branded global products rather than generic versions of existing drugs.

Lupin has innovation and specialty programmes too, but its current earnings transformation is still driven much more by differentiated generics and complex products.

Lupin is building biosimilars into a third growth engine

Lupin received US FDA approval for Armlupeg, its pegfilgrastim biosimilar, during FY26.

Its biosimilar pipeline also spans molecules including ranibizumab, denosumab and other biologic therapies across multiple global markets.

Biosimilars can offer attractive economics because development and manufacturing are much more difficult than conventional small-molecule generics.

However, biologic manufacturing requires large investment and rigorous process control.

Lupin's specialty strategy is concentrated in selected therapies

The company identifies respiratory, neuroscience and ophthalmology as key specialty areas.

It already owns US respiratory brands such as Xopenex HFA and Brovana.

The objective is not to become a Sun-sized innovative-medicines company immediately.

Instead, Lupin is using existing capabilities in respiratory and complex delivery to create selected branded opportunities.

India remains a much larger earnings pillar for Sun

Sun generated approximately ₹5,475 crore of India formulation sales in Q1 FY27.

That represented 36.1% of consolidated sales and grew 16% year on year.

Lupin generated approximately ₹2,380 crore of India sales, representing 29% of total sales.

Lupin's India sales grew 13.9%, with India Region formulations growing about 15.1%.

Sun therefore has more than twice Lupin's domestic pharmaceutical revenue.

Sun's Indian leadership creates a durable commercial moat

Sun is the largest company in the Indian pharmaceutical market.

It has strong positions across chronic and specialty therapies.

A large domestic field force allows the company to launch new products across thousands of doctors and pharmacies.

That commercial infrastructure is particularly valuable when introducing new therapies such as semaglutide.

Lupin's chronic-heavy India mix is improving

Lupin's Indian portfolio increasingly focuses on chronic disease.

Its FY26 chronic share had risen to roughly two-thirds of Indian formulation sales.

Key therapies include:

• cardiology;
• diabetes;
• respiratory;
• gastroenterology;
• women's health;
• CNS;
• urology.

Chronic medicines typically produce more repeat prescriptions than short-course acute therapies.

This can improve revenue visibility and sales-force productivity.

Lupin is also entering the GLP-1 opportunity

Lupin has partnered on semaglutide in India as it expands into obesity and metabolic disease.

Sun has already launched generic semaglutide products in India and has also received approvals in international markets.

Both companies therefore see metabolic disease as a major future growth pool.

Other international markets strongly favoured Lupin in Q1

Lupin's Other Developed Markets revenue increased 48.3% to approximately ₹1,149 crore.

Emerging Markets increased 51.7% to approximately ₹990 crore.

These figures show Q1 growth was not solely dependent on the US.

Sun's Emerging Markets grew 4.2% to US$311 million.

Rest-of-World formulations generated US$218 million.

Sun has greater absolute geographic scale, but Lupin had substantially stronger percentage growth during the quarter.

Lupin's EBITDA recovery is one of the most important changes

Lupin reported ₹2,580 crore EBITDA in Q1, up 42.8% year on year.

EBITDA margin improved 210 basis points to 31.4%.

Gross margin reached 74.6%.

This shows differentiated products are translating revenue growth into better profitability.

Historically, Lupin's lower margins were one of the major reasons the stock traded at a discount to higher-quality pharma peers.

But Lupin's Q1 margin contains one accounting nuance

The broader conclusion remains valid.

Lupin's underlying profitability has improved substantially.

Sun's margin actually declined year on year

Sun's EBITDA margin was 28.9% versus 31.1% in the comparable quarter.

Innovative Medicines continued growing, but higher operating expenses and business mix affected margin.

The company also continues investing heavily in R&D and commercial infrastructure.

This is one reason Sun's sales growth of 10.1% translated into EBITDA growth of only 2.7%.

Sun's reported PAT growth overstates underlying Q1 growth

Reported PAT increased approximately 27% to ₹2,895 crore.

But adjusted net profit increased only 3.1% to approximately ₹3,089 crore.

The gap reflects exceptional items in the comparison periods and current quarter.

Investors should therefore avoid comparing Sun's reported 27% PAT growth directly with Lupin's 16% without adjusting for the underlying accounting effects.

Lupin's PAT growth was cleaner

Lupin reported ₹1,417 crore PAT, up 16% year on year.

PBT increased 42.5% to approximately ₹2,017 crore.

The PAT growth lagged PBT growth because the tax charge increased sharply versus a low prior-year tax base.

This means operating earnings growth was stronger than the net-profit number initially suggests.

Both companies now have strong balance sheets

This is a major improvement for Lupin relative to earlier periods.

A net-cash balance sheet gives it more flexibility to pursue specialty assets, biosimilars and selective acquisitions.

Sun is preparing for a much bigger capital-allocation decision

Sun's proposed acquisition of Organon had received Organon shareholder approval by July 2026 but had not closed as of Q1.

The transaction is expected to materially increase Sun's global scale if completed.

But it can also alter Sun's leverage, acquisition risk and future return profile.

The current comparison therefore evaluates Sun before the proposed Organon transaction is consolidated.

R&D intensity currently favours Lupin

Lupin invested ₹608 crore in Q1 R&D, equal to 7.4% of sales.

Sun invested ₹826 crore, equal to 5.4%.

Sun spends more absolute money.

Lupin currently spends a larger proportion of revenue.

This investment supports Lupin's complex generics, inhalation products, injectables, biosimilars and specialty pipeline.

Capital efficiency creates the biggest surprise

Lupin's current Bull Run ROCE and ROE are materially higher than Sun's.

That reflects the sharp improvement in Lupin's earnings against its capital base.

Investors should still watch whether these returns remain sustainable once exclusivity-driven US products normalise.

Exclusivity can temporarily inflate pharmaceutical returns

Some US generic products can earn unusually high profits during periods of limited competition.

As new competitors launch, price and margin can fall rapidly.

This means Lupin's current earnings mix should not automatically be extrapolated at the same margin forever.

The company needs a continuing pipeline of differentiated products to replace normalising opportunities.

Its pipeline is large enough to make that possible

Lupin has stated that it expects to introduce more than 50 US products across the next three years, including:

• first-to-file opportunities;
• biosimilars;
• complex injectables;
• respiratory products;
• 505(b)(2) products.

If execution remains strong, Lupin can replace individual products with new differentiated launches.

Valuation is where the comparison becomes difficult for Sun

Lupin trades at almost half Sun's trailing earnings multiple.

This is notable because Lupin also has faster current growth and higher reported capital returns.

The valuation discount reflects important risks:

• greater dependence on US generics;
• potential normalisation of high-value product opportunities;
• historical regulatory volatility;
• less mature innovative-specialty exposure;
• more quarter-to-quarter product-mix sensitivity.

Sun's premium reflects durability and optionality

Sun has a broader earnings architecture.

India formulations provide a large branded base.

Innovative Medicines provide global specialty growth.

Emerging Markets diversify geography.

US generics remain significant but are no longer the entire thesis.

The market therefore assigns Sun a premium for earnings durability and innovation optionality.

But the premium is no longer small

At 38.8x versus Lupin at 20.6x, Sun needs materially more durable future earnings to justify the valuation gap.

Investors are effectively paying almost twice the multiple for the broader and more innovative franchise.

The question is whether that premium is justified by lower earnings volatility and long-duration specialty growth.

Share-price momentum does not explain the valuation gap

Sun's one-year Bull Run return is approximately 23.4%.

Lupin's is approximately 13.4%.

Lupin has actually lagged despite stronger Q1 growth.

This can create upside if the earnings improvement proves durable, but it can also indicate investors expect current US profitability to normalise.

What must Sun Pharma prove?

• Innovative Medicines should keep growing double digits.
• India formulations need sustained market-share gains.
• US generic declines should stabilise.
• Clinical programmes need successful milestones.
• Semaglutide and peptide opportunities should scale.
• The Organon transaction must preserve capital discipline if completed.
• EBITDA margin should recover from Q1 compression.

What must Lupin prove?

• US growth must remain strong after individual exclusivities normalise.
• Complex products should become a larger share of the US portfolio.
• Biosimilar launches need profitable execution.
• India formulations should sustain above-market growth.
• 31%-plus Q1 EBITDA margin needs to prove durable.
• Regulatory compliance must remain strong across key plants.
• High current ROCE should survive the next product cycle.

What could make Lupin outperform Sun Pharma?

Continued US complex-product execution.

If Lupin keeps replacing maturing products with new inhalation, injectable, biosimilar and first-to-file launches, a 20x earnings multiple can prove inexpensive relative to its growth rate.

The net-cash balance sheet provides additional flexibility.

What could make Sun Pharma outperform Lupin?

A successful innovative-medicines pipeline.

One or two major specialty products can create global revenue pools larger than several generic launches combined.

Sun's scale and commercial infrastructure also allow it to monetise successful products across multiple geographies.

Which has the stronger current US growth?

Lupin.

Q1 US sales increased 42.9% while Sun's US formulation revenue declined 9.7%.

Which has the stronger specialty franchise?

Sun Pharma.

Innovative Medicines already contribute 21.9% of consolidated sales and include multiple commercial global brands.

Which has the stronger current margins?

Lupin on disclosed Q1 EBITDA margin.

Lupin reported 31.4% versus Sun Pharma at 28.9%, though definitions differ slightly.

Which has the stronger valuation?

Lupin.

At approximately 20.6x trailing earnings, it trades at a substantial discount to Sun around 38.8x.

Which is better: Sun Pharma or Lupin?

Sun Pharma currently has the stronger long-duration pharmaceutical franchise. It has greater scale, India's largest branded business and a genuine global Innovative Medicines platform that increasingly reduces dependence on commodity generics.

Lupin currently has the stronger valuation-adjusted earnings momentum. Sales grew 33%, EBITDA grew 43%, US sales rose 43%, ROCE is above 30% and the stock trades around 20.6x trailing earnings.

That creates an unusually balanced comparison.

Sun offers greater specialty durability and innovation optionality.

Lupin offers substantially more growth and current capital efficiency per rupee of valuation.

At September 2026 valuations, Lupin has the lower valuation hurdle and stronger current operating momentum, while Sun deserves a quality premium for its broader branded and innovative-medicines franchise. The key question is whether Lupin's complex-product earnings remain durable enough to close that quality premium.

Frequently asked questions